Spots Global Cancer Trial Database for A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Official Title: A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT01145989
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Contact Details
Name: Tony Reiman
Affiliation: Atlantic Health Sciences Corporation, Saint John Regional Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
